CELLINK report continued growth and improved margins in the second quarter (December 2018-February 2019)

Wed, Apr 10, 2019 08:30 CET

CELLINK publishes the quarterly report for the period 1st of December 2018 – 28th of February 2019 and for the first 6 months. The report is available on the company's website: http://cellink.com/investor-relations/. This press release presents a summary of the report.

Second quarter

Net sales amounted to SEK 23,837 thousand (SEK 8,724 thousand), which corresponds with a growth of 173%, of which 150% was organic growth, compared to the second quarter of the previous fiscal year
During the quarter, the company acquired 100% of the shares in German company, Dispendix GmbH. The purchase price amounts to approximately EUR 5 million
Operating profit before depreciation (EBITDA) amounted to SEK 2,865 thousand (SEK 460 thousand), corresponding to a margin of 8,7% (3,7%)
Net income amounted to SEK 1,339 thousand (SEK 54 thousand), generating an earnings per share of SEK 0.16 (SEK 0.007) after dilution

First six months

Net sales amounted to SEK 43,874 thousand (SEK 16,821 thousand), corresponding to a growth of 161% of which, 149% was organic growth, compared to the first six months of the previous fiscal year
Operating profit before depreciation (EBITDA) amounted to SEK 4,466 thousand (SEK 432 thousand), corresponding to a margin of 7,4% (1,8%)
Net income amounted to SEK 2,015 thousand (SEK -467 thousand), generating an earnings per share of SEK 0.24 (SEK -0.06) after dilution

Events during the second quarter (December 2018 – February 2019)

On December 1, the acquisition of Dispendix GmbH was completed.
On December 4, CELLINK announced that the company entered a partnership with Medimmune, in order to leverage CELLINKs 3D bioprinting techniques for new drug discoveries.
On December 5, CELLINK signed a partnership with Prellis Biologics Inc. for commercialization of a holographic bioprinting technique.
On January 28, CELLINK was granted project funding of SEK 5 million from the European Union (EU).
On February 4, CELLINK launched a new product to bring fast and sharp live-cell imaging to every incubator.
On February 19, CELLINK was granted a patent for ”3D printer and a method for 3D printing of a construct” from the Swedish Patent and Registration Office.

Events after closing day

On March 18, CELLINK launched a new product, Lumen X for digital light processing 3D bioprinting.
On March 22, CELLINK announced that the company and the Adult Stem Cell Research Centre at Seoul National University entered a new agreement for bioprinting research.

Events during the first six months (September 2018 – February 2019)

On September 4, CELLINK published three new research achievements made with the company’s products.
On September 11, the company announced that Dr. Mina Bisell entered the CELLINK Advisory Board.
On October 2, the company announced a project funding grant of SEK 3 million from the European Union (EU).
On October 17, CELLINK launched two new products – a bioink series and an extension of one existing product series.
On November 6, CELLINK launched a new product series of bioink and an extension of three existing product series.
On November 29, CELLINK AB acquired the German company, Dispendix GmbH for approximately EUR 5 million.
On December 1, the acquisition of Dispendix GmbH was completed.
On December 4, CELLINK announced that the company entered a partnership with Medimmune in order to leverage CELLINK’s 3D bioprinting techniques for new drug discoveries.
On December 5, CELLINK signed a partnership with Prellis Biologics Inc. for commercialization of a holographic bioprinting technique.
On January 28, CELLINK was granted a project funding of SEK 5 million from the European Union (EU).
On February 4, CELLINK launched a new product to bring fast and sharp live-cell imaging to every incubator.
On February 19, CELLINK was granted a patent for ”3D printer and a method for 3D printing of a construct” from the Swedish Patent and Registration Office.

For further information, please contact:

Erik Gatenholm, CEO Gusten Danielsson, CFO

Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138

Email: eg@cellink.com Email: gd@cellink.com

Important information

This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on April 10, 2019 at. 08:30 CET.

About CELLINK

CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.

CELLINK report continued growth and improved margins in the second quarter (December 2018-February 2019)

Documents & Links